"According to the study, users of the drugs seem to be at a higher risk, not lower, of developing a cognitive impairment including dementia, and Alzheimer's. Specifically, the data shows that the impairments occurred twice as frequently (at 2.6 percent) in patients who took the GLP-1 drugs, compared to those who didn't (at 1.3 percent)."
"We interpret this to mean that GLP-1 analog recipients lived significantly longer than non-recipients, and that they lived long enough for them to develop cognitive impairment."
Research indicates that GLP-1 agonist drugs like semaglutide offer various health benefits, including reduced kidney disease progression and lower opiate addiction risk. However, a new study suggests these drugs may actually increase the risk of cognitive impairment, dementia, and Alzheimer's. Analyzing data from nearly 65,000 type 2 diabetes patients, the study found that cognitive impairments occurred more frequently in GLP-1 users. The researchers propose that longer lifespans due to the drug may lead to increased cognitive issues as patients age.
Read at Futurism
Unable to calculate read time
Collection
[
|
...
]